Skip to content
10-Q

Quarterly Report

XBIOTECH INC. XBIT

0001171843-24-006336

← back to feed
Filed
Nov 13, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 13, 2024 30.48M sh
Stock Repurchased Q3 2024 · Sep 30, 2024 $0
Stock Repurchased Q3 2024 · Sep 30, 2023 $14K
Cash And Equivalents Q3 2024 · Sep 30, 2024 $183.12M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $200.02M
Current Liabilities Q3 2024 · Sep 30, 2024 $15.99M
Current Liabilities Q3 2024 · Dec 31, 2023 $6.1M
Total Liabilities Q3 2024 · Sep 30, 2024 $17.74M
Total Liabilities Q3 2024 · Dec 31, 2023 $7.77M
Current Assets Q3 2024 · Sep 30, 2024 $185.03M
Current Assets Q3 2024 · Dec 31, 2023 $201.72M
Total Assets Q3 2024 · Sep 30, 2024 $209.85M
Total Assets Q3 2024 · Dec 31, 2023 $226.62M
Capex Q3 2024 · Sep 30, 2023 $247K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$15.29M
Stockholders Equity Q3 2024 · Sep 30, 2023 $222.66M
Stockholders Equity Q3 2024 · Jun 30, 2023 $229.06M
Stockholders Equity Q3 2024 · Dec 31, 2022 $240.4M
Eps Basic Q3 2024 · Sep 30, 2023 −$0.24
Eps Basic Q3 2024 · Sep 30, 2023 −$0.65
Sga Expense Q3 2024 · Sep 30, 2023 $973K
Sga Expense Q3 2024 · Sep 30, 2023 $3.88M
Rd Expense Q3 2024 · Sep 30, 2023 $7.55M
Rd Expense Q3 2024 · Sep 30, 2023 $25.04M
Net Income Q3 2024 · Sep 30, 2023 −$7.36M
Net Income Q3 2024 · Sep 30, 2023 −$19.92M
Operating Income Q3 2024 · Sep 30, 2023 −$8.52M
Operating Income Q3 2024 · Sep 30, 2023 −$28.92M